Advertisement

Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement

Apr

22

Today In Oncology

Pretreatment MRI Prognostic Information After Radical Prostatectomy

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer

Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions

Advertisement

© 2026 HSP News Service, L.L.C.